<DOC>
	<DOCNO>NCT02465112</DOCNO>
	<brief_summary>TERAVECT phase III randomize study patient digestive neuroendocrine tumor complete surgical resection liver metastasis treat In111-Pentetreotide-based adjuvant radiotherapy . In study , target radionuclide therapy use earlier stage disease.The objective target residual tumor cell and/or micrometastases escape surgical resection . Given poor prognosis associate recurrence , treatment prevent relapse .</brief_summary>
	<brief_title>Metabolic Radiotherapy After Complete Resection Liver Metastases Patient With Digestive Neuroendocrine Tumor</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Signed date informed consent , Age ≥ 18 year , Patients well differenciated digestive neuroendocrine tumor liver metastasis , complete surgical resection liver metastases primary tumor perform , 1 2 time , Immunohistochemical confirmation neuroendocrine tumor WHO 2010 grade specification Ki67 determine surgical specimen , ECOG Performance Status ( PS ) 01 , Adequate hematological status : Platelets &gt; 100000/mm3 , Hemoglobin &gt; 10g/dL , Adequate Clearance Creatinine &gt; 60 mL/min , Adequate liver function : Total Serum Bilirubin &lt; 1.5x upper limit normal ( ULN ) , transaminases &lt; 3 x ULN , Grade In111Pentetreotide uptake ≥ 2 ( score accord Krenning et al scale . : intense physiological liver uptake ) , Treatment start within 14 week surgical resection , Men woman require use adequate birth control measure course study period 12 month last administration study drug . Female patient childbearing potential must negative serum pregnant test ( βHCG ) within 7 day start study treatment , Life expectancy &gt; 6 month Registration National Health Care System ( CMU include France ) History previous second cancer progressive cancer occur within 5 year prior inclusion , except basal cell squamous cell carcinoma , Patients know sensibility hypersensibility In111 Pentetreotide component treatment drug , Pregnant breastfeed woman without adequate birth control measure , Patient know medical history psychological psychiatric disorder may affect patient participation study due lack cooperation loss autonomy prevent hospitalization initiation study treatment ( good radiation protection condition ) , Treatment investigational drug within 28 day prior study entry , Patient protect law ( tutelage guardianship ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>